Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00174434 · ClinicalTrials.gov registry record · Phase 1
Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT00174434 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 22 participants.
The verdict
NCT00174434, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
This study is to evaluate the safety of SU011248 in combination with paclitaxel in patients with metastatic or locally recurrent breast cancer who have not received chemotherapy treatment in the advanced disease setting.
Interventions
- DRUG Paclitaxel
- DRUG SU011248
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2005-09 |
| Est. Completion | 2007-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00174434
The ClinicalTrials.gov registry entry for NCT00174434 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Paclitaxel is the first listed.
NCT00174434 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00174434 about?
NCT00174434 is a clinical study titled "Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer". This study is to evaluate the safety of SU011248 in combination with paclitaxel in patients with metastatic or locally recurrent breast cancer who have not received chemotherapy treatment in the advanced disease setting.
What is the current status of trial NCT00174434?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2005-09. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00174434?
The interventions under investigation include: Paclitaxel (DRUG), SU011248 (DRUG).
Who is sponsoring clinical trial NCT00174434?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.